Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Revamilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D known ✓ | Q08499 | 16/20 | 0.59 |
| ▸ | PDE4B known ✓ | Q07343 | 16/20 | 0.57 |
| ▸ | PDE4A known ✓ | P27815 | 16/20 | 0.57 |
| ▸ | PDE4C known ✓ | Q08493 | 13/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72937 | 0.90 | PDE4D (0.69) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL75217 | 0.89 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CPDE11A | |
| SCHEMBL75216 | 0.89 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14174073 | 0.87 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL4573772 | 0.83 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5504845 | 0.83 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14174057 | 0.83 | PDE4D (0.60) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL13777247 | 0.81 | PDE4D (0.81) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL73200 | 0.80 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4CPDE11A | |
| SCHEMBL5017912 | 0.80 | PDE4B (0.71) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| US-11504332-B2 | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof | VK RESEARCH ASSOCIATES INC. (US) | 2022-11-22 | — | — | US | claimed |
| US-20220304935-A1 | PHOSPHODIESTERASE-4 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | VK Research Associates Inc | 2022-09-29 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| WO-2022022669-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2022-02-03 | — | — | WO | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | GLAS USA LLC | 2021-02-04 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| WO-2019147824-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PROGENITY, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4D 10/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | PDE4D 5/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | PDE4D 944/4885PDE4B 1380/4885PDE4A 1415/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | PDE4D 2903/4885PDE4B 2803/4885PDE4A 2980/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | PDE4D 658/4885PDE4B 1445/4885PDE4A 1656/4885 |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | JAK1, JAK2, CNKSR1 | PDE4D 3935/4885PDE4B 3524/4885PDE4A 2592/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE4D 1677/4885PDE4B 1894/4885PDE4A 1073/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | PDE4D 943/4885PDE4B 611/4885PDE4A 559/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE4D 1677/4885PDE4B 1894/4885PDE4A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.